ID
22107
Beskrivning
The present pharmacokinetic study is designed to assess the pharmacokinetics of RSG XR as monotherapy in patients with mild Alzheimer's disease (AD) as such information will not be obtained from the current phase III trials . The study aims to enroll fourteen patients (seven of each APOE genotype). Each patient will receive a single oral dose of 4mg of RSG XR in the morning under fasted conditions and PK samples will be taken up to 36h. GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1
Länk
https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1
Nyckelord
Versioner (2)
- 2017-05-08 2017-05-08 -
- 2017-05-20 2017-05-20 -
Uppladdad den
20 maj 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Follow-Up Clinical Chemistry Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
Follow-Up Clinical Chemistry Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
Similar models
Follow-Up Clinical Chemistry Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
C0008000 (UMLS CUI-2)
C0008000 (UMLS CUI [1,2])
C0008000 (UMLS CUI [1,2])
C2826772 (UMLS CUI-2)
C0008000 (UMLS CUI [1,2])
C0008000 (UMLS CUI [1,2])